Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03829930 · ClinicalTrials.gov registry record · Phase 1
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
A Phase 1 study, sponsored by George Washington University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03829930 is a Phase 1 study that was terminated before completion, run by George Washington University. The registered enrollment target is 6 participants.
The verdict
NCT03829930, a Phase 1 study, was terminated before completion, sponsored by George Washington University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer
Interventions
- DRUG Enzalutamide
- DRUG Entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03829930
The ClinicalTrials.gov registry entry for NCT03829930 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enzalutamide is the first listed.
NCT03829930 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03829930 about?
NCT03829930 is a clinical study titled "Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer". To determine the safety and tolerability of Entinostat in combination with Enzalutamide in metastatic castrate resistant prostate cancer
What is the current status of trial NCT03829930?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-05-01. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT03829930?
The interventions under investigation include: Enzalutamide (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT03829930?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.